Incannex Healthcare (IXHL)
Develops combination medicines and a psilocybin-assisted therapy candidate for chronic diseases.
Something off on this page? Send us feedback.
Clinical-stage developer of IHL-42X for obstructive sleep apnea, IHL-675A for rheumatoid arthritis and PSX-001 for generalized anxiety disorder. The portfolio combines oral fixed-dose medicines with a psilocybin-assisted therapy program.
Develops clinical-stage candidates for obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. IHL-42X and IHL-675A are oral fixed-dose combinations, while PSX-001 is an oral synthetic psilocybin candidate used with psychological therapy.
IHL-42X is the lead program, pairing dronabinol with acetazolamide for obstructive sleep apnea. IHL-675A combines cannabidiol and hydroxychloroquine sulfate for inflammatory conditions including rheumatoid arthritis.
Work remains development-stage rather than a commercial product portfolio. The current Delaware parent succeeded the Australian predecessor through a redomiciliation. Manufacturing and process development depend on third parties because the company has no manufacturing capabilities.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $74.5M · Total debt $114.0K · Total assets $80.3M · Shareholders' equity $75.2M
- Revenue
- $0
- Operating income
- −$4.0M
- Net income
- −$3.9M
No dividends on record.
| Institutions | 3.81% | 454.7K shares | |
|---|---|---|---|
| 17 holders · as of Jun 30, 2026 | |||
| Insiders | 12.11% | 1.45M shares | |
| 7 holders · as of Nov 14, 2025 | |||
| Other | 84.08% | 10.04M shares | |
| remainder | |||
11.94M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Polar Asset Management Partners Inc.Institution | 7.53% | 900,000 | filed Aug 14, 2026 |
Joel LathamInsiderdirector, officer: CEO and President | 6.75% | 806,206 | filed Nov 14, 2025 |
Troy ValentineInsiderdirector | 3.35% | 400,062 | filed Nov 14, 2025 |
LPL Financial LLCInstitution | 1.24% | 148,178 | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 0.80% | 95,252 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Apnimed
Late-stage oral OSA therapy with an NDA under FDA review
- ResMed
PAP devices and sleep-diagnosis systems for OSA
- Inspire Medical Systems
Implantable neurostimulation therapy for moderate-to-severe OSA
- Definium Therapeutics
Phase 3 oral LSD formulation for generalized anxiety disorder
- Helus Pharma
Phase 2 deuterated-DMT program for generalized anxiety disorder
- AbbVie
Established RA franchise spanning oral Rinvoq and injected Humira
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Incannex Healthcare | $3.45 | +1.47% | $40.6M | — | — | — | +1,566.7% |
| Apnimed | $21.81 | −14.52% | $1.02B | — | — | — | — |
| ResMed | $222.33 | +0.16% | $32.20B | 21.3 | 18.3 | 5.7 | +8.6% |
| Inspire Medical Systems | $68.97 | −3.27% | $2.06B | 15.4 | 53.5 | 2.3 | −7.6% |
| Definium Therapeutics | $37.59 | −6.78% | $5.35B | — | — | — | — |
| Helus Pharma | $12.98 | −5.32% | $849.8M | — | — | — | — |
| AbbVie | $264.74 | −0.18% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Median | 21.3 | 18.3 | 5.7 | +8.6% |